These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17311616)

  • 21. MRI findings in nonalcoholic steatohepatitis: correlation with histopathology and clinical staging.
    Elias J; Altun E; Zacks S; Armao DM; Woosley JT; Semelka RC
    Magn Reson Imaging; 2009 Sep; 27(7):976-87. PubMed ID: 19356874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).
    Yoneda M; Yoneda M; Mawatari H; Fujita K; Endo H; Iida H; Nozaki Y; Yonemitsu K; Higurashi T; Takahashi H; Kobayashi N; Kirikoshi H; Abe Y; Inamori M; Kubota K; Saito S; Tamano M; Hiraishi H; Maeyama S; Yamaguchi N; Togo S; Nakajima A
    Dig Liver Dis; 2008 May; 40(5):371-8. PubMed ID: 18083083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of disease progression in nonalcoholic fatty liver disease.
    Jou J; Choi SS; Diehl AM
    Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: experiment with rats].
    Chen LL; Deng XQ; Li NX
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1434-7. PubMed ID: 17785073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients.
    Valva P; De Matteo E; Galoppo M; Pedreira A; Giacove G; Lezama C; Marco I; Galoppo MC; Preciado MV
    Hum Pathol; 2008 Dec; 39(12):1816-22. PubMed ID: 18715620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C.
    Younossi ZM; Afendy A; Stepanova M; Hossain N; Younossi I; Ankrah K; Gramlich T; Baranova A
    Liver Int; 2009 Oct; 29(9):1403-12. PubMed ID: 19515216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass.
    Larson SP; Bowers SP; Palekar NA; Ward JA; Pulcini JP; Harrison SA
    Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1329-32. PubMed ID: 17702661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis.
    Mishra P; Nugent C; Afendy A; Bai C; Bhatia P; Afendy M; Fang Y; Elariny H; Goodman Z; Younossi ZM
    Liver Int; 2008 Sep; 28(8):1080-6. PubMed ID: 18647236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
    Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
    Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease in type 2 diabetes mellitus.
    Cusi K
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):141-9. PubMed ID: 19262374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
    Mallat A; Lotersztajn S
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G9-G12. PubMed ID: 17975129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERp57 is up-regulated in free fatty acids-induced steatotic L-02 cells and human nonalcoholic fatty livers.
    Wang H; Chan PK; Pan SY; Kwon KH; Ye Y; Chu JH; Fong WF; Tsui WM; Yu ZL
    J Cell Biochem; 2010 Aug; 110(6):1447-56. PubMed ID: 20506389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management.
    Portincasa P; Grattagliano I; Palmieri VO; Palasciano G
    Clin Biochem; 2005 Mar; 38(3):203-17. PubMed ID: 15708540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression.
    Ikura Y; Ohsawa M; Suekane T; Fukushima H; Itabe H; Jomura H; Nishiguchi S; Inoue T; Naruko T; Ehara S; Kawada N; Arakawa T; Ueda M
    Hepatology; 2006 Mar; 43(3):506-14. PubMed ID: 16496325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors.
    Ellert-Miklaszewska A; Grajkowska W; Gabrusiewicz K; Kaminska B; Konarska L
    Brain Res; 2007 Mar; 1137(1):161-9. PubMed ID: 17239827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expression of MCP-1 in the patients of chronic hepatitis B complicated with nonalcoholic fatty liver disease].
    Shen HY; Deng YC; Wang QM; Li QS; Xu Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Sep; 28(9):975-8. PubMed ID: 22980664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease.
    van Geenen EJ; Smits MM; Schreuder TC; van der Peet DL; Bloemena E; Mulder CJ
    Pancreas; 2010 Nov; 39(8):1185-90. PubMed ID: 20871475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease.
    Charlton M; Viker K; Krishnan A; Sanderson S; Veldt B; Kaalsbeek AJ; Kendrick M; Thompson G; Que F; Swain J; Sarr M
    Hepatology; 2009 Apr; 49(4):1375-84. PubMed ID: 19330863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease.
    Uribe M; Zamora-Valdés D; Moreno-Portillo M; Bermejo-Martínez L; Pichardo-Bahena R; Baptista-González HA; Ponciano-Rodríguez G; Uribe MH; Medina-Santillán R; Méndez-Sánchez N
    Ann Hepatol; 2008; 7(1):67-71. PubMed ID: 18376369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease.
    Yilmaz Y; Eren F; Colak Y; Senates E; Celikel CA; Imeryuz N
    Scand J Gastroenterol; 2012 Dec; 47(12):1488-93. PubMed ID: 23137022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.